Dabur India Limited officials will attend the Nuvama India Conference 2026 in London on June 08, 2026, to engage with analysts and institutional investors. The physical meeting is scheduled to take place at the London Marriott Hotel, Grosvenor Square, from 10:00 a.m. to 05:00 p.m. IST. The company confirmed that no unpublished price sensitive information will be shared during the conference.

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The schedule for the conference remains subject to change due to exigencies on the part of the company or the organizer.

Conference Details

The following table outlines the specifics of the investor meet:

Ashok Kumar Jain, Group Company Secretary and Chief Compliance Officer, signed the filing on behalf of Dabur India Limited.

Dabur India has issued a clarification addressing concerns raised by the US Food and Drug Administration (USFDA) pertaining to data integrity at its Silvassa manufacturing facility. The company confirmed that the plant continues to operate without any suspension, seeking to reassure stakeholders about the continuity of its manufacturing operations.

USFDA Data Integrity Concerns

The USFDA raised data integrity-related concerns specific to Dabur India's Silvassa plant. Data integrity issues in pharmaceutical manufacturing typically relate to the accuracy, completeness, and reliability of records generated during production and quality control processes. The company acknowledged the regulatory observations and indicated it is actively working to address the concerns flagged by the authority.

Plant Operations and Revenue Impact

Dabur India clarified that the Silvassa plant remains operational following the USFDA's observations. The company stated that the financial impact stemming from the regulatory concerns is minimal, providing reassurance to investors and stakeholders regarding the limited disruption to its business operations.

Commitment to Quality and Compliance

Dabur India pledged to uphold its quality and compliance standards in response to the USFDA's observations. The company's statement underscores its intent to engage constructively with the regulatory authority to resolve the identified concerns. Maintaining compliance with international regulatory bodies remains a key priority for the company's pharmaceutical and consumer healthcare operations.